New patient trials surrounding Retatrutide , specifically the 120mg formulation ZPHC ZPHC, indicate a considerable effect on weight reduction and related health conditions . Researchers believe that this dual compound, targeting both GLP-1 and GIP receptors , could provide a noteworthy breakthrough in the management of overweight and related healt